Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 256

1.

Role of the distal half of the c-Mpl intracellular domain in control of platelet production by thrombopoietin in vivo.

Luoh SM, Stefanich E, Solar G, Steinmetz H, Lipari T, Pestina TI, Jackson CW, de Sauvage FJ.

Mol Cell Biol. 2000 Jan;20(2):507-15.

2.
3.

Promegapoietin, a family of chimeric growth factors, supports megakaryocyte development through activation of IL-3 and c-Mpl ligand signaling pathways.

Doshi PD, Giri JG, Abegg AL, Favara JP, Huynh MS, Kahn LE, Minnerly JC, Pegg LE, Villani-Price D, Siegel NR, Staten NR, Thomas JW, McKearn JP, Smith WG.

Exp Hematol. 2001 Oct;29(10):1177-84.

PMID:
11602319
4.

Control of thrombopoietin-induced megakaryocytic differentiation by the mitogen-activated protein kinase pathway.

Rouyez MC, Boucheron C, Gisselbrecht S, Dusanter-Fourt I, Porteu F.

Mol Cell Biol. 1997 Sep;17(9):4991-5000.

5.
6.

Normal platelets and megakaryocytes are produced in vivo in the absence of thrombopoietin.

Bunting S, Widmer R, Lipari T, Rangell L, Steinmetz H, Carver-Moore K, Moore MW, Keller GA, de Sauvage FJ.

Blood. 1997 Nov 1;90(9):3423-9.

8.

Thrombocytopenia in c-mpl-deficient mice.

Gurney AL, Carver-Moore K, de Sauvage FJ, Moore MW.

Science. 1994 Sep 2;265(5177):1445-7.

PMID:
8073287
9.
10.

Functional regions of the mouse thrombopoietin receptor cytoplasmic domain: evidence for a critical region which is involved in differentiation and can be complemented by erythropoietin.

Porteu F, Rouyez MC, Cocault L, Bénit L, Charon M, Picard F, Gisselbrecht S, Souyri M, Dusanter-Fourt I.

Mol Cell Biol. 1996 May;16(5):2473-82.

11.
12.
13.

Thrombopoietin, but not cytokines binding to gp130 protein-coupled receptors, activates MAPKp42/44, AKT, and STAT proteins in normal human CD34+ cells, megakaryocytes, and platelets.

Majka M, Ratajczak J, Villaire G, Kubiczek K, Marquez LA, Janowska-Wieczorek A, Ratajczak MZ.

Exp Hematol. 2002 Jul;30(7):751-60.

PMID:
12135673
14.

Differential signalling of NH2-terminal flag-labelled thrombopoietin receptor activated by TPO or anti-FLAG antibodies.

Millot GA, Vainchenker W, Duménil D, Svinarchuk F.

Cell Signal. 2004 Mar;16(3):355-63.

PMID:
14687665
15.

Distinct effects of thrombopoietin depending on a threshold level of activated Mpl in BaF-3 cells.

Millot GA, Vainchenker W, Duménil D, Svinarchuk F.

J Cell Sci. 2002 Jun 1;115(Pt 11):2329-37.

16.

Involvement of prolonged ras activation in thrombopoietin-induced megakaryocytic differentiation of a human factor-dependent hematopoietic cell line.

Matsumura I, Nakajima K, Wakao H, Hattori S, Hashimoto K, Sugahara H, Kato T, Miyazaki H, Hirano T, Kanakura Y.

Mol Cell Biol. 1998 Jul;18(7):4282-90.

17.
18.

Regulation of platelet activation in vitro by the c-Mpl ligand, thrombopoietin.

Chen J, Herceg-Harjacek L, Groopman JE, Grabarek J.

Blood. 1995 Dec 1;86(11):4054-62.

19.

c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia.

Ballmaier M, Germeshausen M, Schulze H, Cherkaoui K, Lang S, Gaudig A, Krukemeier S, Eilers M, Strauss G, Welte K.

Blood. 2001 Jan 1;97(1):139-46.

20.

Supplemental Content

Support Center